EGX-B

Last updated
EGX-B
Clinical data
Other namesEGXB
Drug class Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. [1] [2] [3] It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. [3] [4] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. [1] [2] As of December 2023, it is in the preclinical research stage of development. [1] [2]

Contents

See also

References

  1. 1 2 3 "EGX B". AdisInsight. 8 December 2023. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on EGX-B with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. 1 2 Bowen C, Khan T, Perni R, Aron R, Gibbs A, Shin R, Halberstadt A, Premoli I, Kleine P, Rao S, Short G (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (275–275). doi:10.1038/s41386-023-01756-4. PMC   10729596 . PMID   38040810.
  4. ↑ "Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin". LinkedIn. atai Life Sciences. 21 November 2023. Retrieved 16 February 2025.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.